Dr. Samuel Harold Sigal, MD

Dr. Sigal practices at NYU Langone - Tisch Hospital in New York, New York.

Dr. Sigal's NPI, 1457448540, was assigned on October 9, 2006. Dr. Sigal graduated from University of Chicago, Pritzker School of Medicine in 1983. Dr. Sigal holds New York license 177266.

Dr. Sigal's primary practice is NYU Langone - Tisch Hospital, at 550 1st Ave, New York, NY 10016 in New York County. The practice phone is (212) 263-1481.

Dr. Sigal's primary practice is NYU Langone - Tisch Hospital in New York, New York. Dr. Sigal is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Sigal to 2 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sigal practices, 2 sites in all. Vendor and product names are available with a free account.

Hepatology is Dr. Sigal's primary specialty in the NPI Registry, under taxonomy code 207RI0008X. Dr. Sigal is licensed in New York.

CMS data shows 871 Medicare services from Dr. Sigal across 13 procedure codes in 2024, for 349 Medicare patients. Medicare paid $72,861 for them.

CMS counts 349 Medicare patients who saw Dr. Sigal in 2024. The largest group is 65 to 74, with 154 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 18% are also on Medicaid. Their average risk score is 2.46, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sigal's median patient age at 60, with 56% women.

In 2024, Dr. Sigal wrote 431 Medicare Part D claims for 109 patients. 74% of them were for generic drugs. CMS names the drug for 264 of them, across 10 drugs with 11 or more claims each, at $262,335 in total drug cost. In 2023, CMS named 822 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Sigal for performance year 2024, reported as part of a group. Dr. Sigal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sigal as offering telehealth.

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 31 papers to Dr. Sigal, published from 2013 to 2024. 2014 was the busiest year, with 3. The most frequent topics are Liver Cirrhosis, Liver and Liver Transplantation. Dr. Sigal has published most often in Hepat Med. Dr. Sigal's most frequent co-authors are Hearns Charles, MD, Farhad Sahebjam, MD and Matthew Jiro Akiyama, MD.

Dmand AI links Dr. Sigal to 5 clinical trials, 2 of them phase 3 studies. Conditions studied include Non-alcoholic Fatty Liver Disease, Fatty Liver and Hepadnaviridae Infections. Intercept Pharmaceuticals sponsors the most, 2. Open Payments lists research payments to Dr. Sigal that name 1 trial.

CMS Open Payments shows 136 general payments to Dr. Sigal from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 55% of the total. Gilead Sciences, Inc. paid the most, $35,987. It also lists 7 research payments totaling $16,128 from 2016 to 2022, naming 1 clinical trial.

Dr. Sigal graduated from University of Chicago, Pritzker School of Medicine in 1983.